Corvus Pharmaceuticals, Inc. (CRVS) stock
CRVSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$10.64+0.02 (+0.19%)
Close on Nov 13, 2026Market cap $895.05MP/E –Yield –
Corvus Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Corvus Pharmaceuticals's total assets was $223.88M at Sep 30, 2026. For fiscal 2025 it was $71.12M, up 3.2% from the year before. Over ten years it grew -3.2% a year on average. The highest annual figure on record is $140.15M in fiscal 2016.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $71.12M | +3.2% |
| FY2024 | Dec 31, 2024 | $68.91M | +51.3% |
| FY2023 | Dec 31, 2023 | $45.55M | -33.2% |
| FY2022 | Dec 31, 2022 | $68.24M | -37.7% |
| FY2021 | Dec 31, 2021 | $109.46M | +28.0% |
| FY2020 | Dec 31, 2020 | $85.53M | +2.3% |
| FY2019 | Dec 31, 2019 | $83.65M | -29.3% |
| FY2018 | Dec 31, 2018 | $118.23M | +24.8% |
| FY2017 | Dec 31, 2017 | $94.78M | -32.4% |
| FY2016 | Dec 31, 2016 | $140.15M | +42.3% |
| FY2015 | Dec 31, 2015 | $98.46M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $223.88M | +178.2% |
| Q2 FY2026 | Jun 30, 2026 | $239.27M | +167.5% |
| Q1 FY2026 | Mar 31, 2026 | $253.20M | +326.0% |
| Q4 FY2025 | Dec 31, 2025 | $71.12M | +3.2% |
| Q3 FY2025 | Sep 30, 2025 | $80.47M | +36.8% |
| Q2 FY2025 | Jun 30, 2025 | $89.46M | +38.6% |
| Q1 FY2025 | Mar 31, 2025 | $59.44M | +48.3% |
| Q4 FY2024 | Dec 31, 2024 | $68.91M | +51.3% |
| Q3 FY2024 | Sep 30, 2024 | $58.82M | +13.2% |
| Q2 FY2024 | Jun 30, 2024 | $64.56M | +11.2% |
| Q1 FY2024 | Mar 31, 2024 | $40.08M | -31.1% |
| Q4 FY2023 | Dec 31, 2023 | $45.55M | -33.2% |
| Q3 FY2023 | Sep 30, 2023 | $51.94M | -35.4% |
| Q2 FY2023 | Jun 30, 2023 | $58.04M | -37.3% |
| Q1 FY2023 | Mar 31, 2023 | $58.20M | -42.5% |
| Q4 FY2022 | Dec 31, 2022 | $68.24M | -37.7% |
| Q3 FY2022 | Sep 30, 2022 | $80.35M | -32.7% |
| Q2 FY2022 | Jun 30, 2022 | $92.54M | -15.4% |
| Q1 FY2022 | Mar 31, 2022 | $101.29M | -7.3% |
| Q4 FY2021 | Dec 31, 2021 | $109.46M | +28.0% |
| Q3 FY2021 | Sep 30, 2021 | $119.32M | +113.6% |
| Q2 FY2021 | Jun 30, 2021 | $109.39M | +70.5% |
| Q1 FY2021 | Mar 31, 2021 | $109.24M | +48.0% |
| Q4 FY2020 | Dec 31, 2020 | $85.53M | +2.3% |
| Q3 FY2020 | Sep 30, 2020 | $55.86M | -39.6% |
| Q2 FY2020 | Jun 30, 2020 | $64.18M | -37.8% |
| Q1 FY2020 | Mar 31, 2020 | $73.80M | -34.3% |
| Q4 FY2019 | Dec 31, 2019 | $83.65M | -29.3% |
| Q3 FY2019 | Sep 30, 2019 | $92.47M | -27.3% |
| Q2 FY2019 | Jun 30, 2019 | $103.12M | -25.2% |
| Q1 FY2019 | Mar 31, 2019 | $112.31M | -24.5% |
| Q4 FY2018 | Dec 31, 2018 | $118.23M | +24.8% |
| Q3 FY2018 | Sep 30, 2018 | $127.22M | +21.4% |
| Q2 FY2018 | Jun 30, 2018 | $137.92M | +19.4% |
| Q1 FY2018 | Mar 31, 2018 | $148.69M | +17.0% |
| Q4 FY2017 | Dec 31, 2017 | $94.78M | -32.4% |
| Q3 FY2017 | Sep 30, 2017 | $104.79M | – |
| Q2 FY2017 | Jun 30, 2017 | $115.49M | – |
| Q1 FY2017 | Mar 31, 2017 | $127.10M | – |
| Q4 FY2016 | Dec 31, 2016 | $140.15M | – |
See a number that looks wrong?